JP2022511394A5 - - Google Patents
Info
- Publication number
- JP2022511394A5 JP2022511394A5 JP2021517792A JP2021517792A JP2022511394A5 JP 2022511394 A5 JP2022511394 A5 JP 2022511394A5 JP 2021517792 A JP2021517792 A JP 2021517792A JP 2021517792 A JP2021517792 A JP 2021517792A JP 2022511394 A5 JP2022511394 A5 JP 2022511394A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- dose
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811159863.8 | 2018-09-30 | ||
| CN201811159863 | 2018-09-30 | ||
| CN201811224605.3 | 2018-10-19 | ||
| CN201811224605 | 2018-10-19 | ||
| PCT/CN2019/109214 WO2020063988A1 (zh) | 2018-09-30 | 2019-09-29 | Cldn18的抗体和化疗药物的联合治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511394A JP2022511394A (ja) | 2022-01-31 |
| JP2022511394A5 true JP2022511394A5 (https=) | 2022-10-07 |
Family
ID=69950365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517792A Pending JP2022511394A (ja) | 2018-09-30 | 2019-09-29 | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220033491A1 (https=) |
| EP (1) | EP3858384A4 (https=) |
| JP (1) | JP2022511394A (https=) |
| KR (1) | KR20210072027A (https=) |
| CN (1) | CN112888458B (https=) |
| WO (1) | WO2020063988A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CN114634566B (zh) * | 2020-12-16 | 2023-09-19 | 广州百暨基因科技有限公司 | 一种抗Claudin18_2的抗原结合片段、抗体及其应用 |
| TW202241519A (zh) | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| WO2022206975A1 (zh) * | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
| JP2024540062A (ja) * | 2021-11-05 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 抗ｃｌｄｎ１８．２抗体及びその用途 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN121620529A (zh) * | 2023-07-31 | 2026-03-06 | 南京传奇生物科技有限公司 | 嵌合细胞因子受体及其使用方法 |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| WO2025082356A1 (zh) * | 2023-10-16 | 2025-04-24 | 江苏奥赛康生物医药有限公司 | Cldn18_2抗体与化学治疗药物的组合及其应用 |
| CN117430708B (zh) * | 2023-12-21 | 2024-04-09 | 苏州近岸蛋白质科技股份有限公司 | 一种抗Claudin18.2抗体 |
| CN118620072A (zh) * | 2023-12-27 | 2024-09-10 | 上海博钒生物科技有限公司 | 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101602808B (zh) | 2008-06-12 | 2012-06-20 | 上海市肿瘤研究所 | 特异性结合蛋白及其使用 |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| EP3791896B1 (en) | 2012-05-23 | 2024-01-10 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2852409B1 (en) * | 2012-05-23 | 2020-03-25 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US10858415B2 (en) * | 2014-01-29 | 2020-12-08 | Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh | Peptide mimotopes of claudin 18.2 and uses thereof |
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
-
2019
- 2019-09-29 JP JP2021517792A patent/JP2022511394A/ja active Pending
- 2019-09-29 KR KR1020217013109A patent/KR20210072027A/ko not_active Ceased
- 2019-09-29 WO PCT/CN2019/109214 patent/WO2020063988A1/zh not_active Ceased
- 2019-09-29 US US17/281,372 patent/US20220033491A1/en not_active Abandoned
- 2019-09-29 CN CN201980065066.XA patent/CN112888458B/zh active Active
- 2019-09-29 EP EP19866728.9A patent/EP3858384A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511394A5 (https=) | ||
| JP2013520442A5 (https=) | ||
| JP2016520082A5 (https=) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2020508317A5 (https=) | ||
| JP2018508512A5 (https=) | ||
| JP2012509889A5 (https=) | ||
| JP2019506403A5 (https=) | ||
| JP2017514795A5 (https=) | ||
| JP2022515077A5 (https=) | ||
| JP2024533067A5 (https=) | ||
| JP2017031160A5 (https=) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2017501167A5 (https=) | ||
| JP2013173775A5 (https=) | ||
| JP2021528423A5 (https=) | ||
| JP2014522843A5 (https=) | ||
| JP2020527332A5 (https=) | ||
| JP2022512851A5 (https=) | ||
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| JP2021511344A5 (https=) | ||
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| JP2020535180A5 (https=) | ||
| JP2020521798A5 (https=) | ||
| JP2017515843A5 (https=) |